EU HTA Regulation (HTAR)

HTAR creates an EU-level framework for assessing the relative clinical effectiveness and safety of new health technologies. It does not replace national HTA bodies and does not address pricing or reimbursement — those remain national competences. Instead, JCAs produce a single shared clinical-evidence assessment used as input to national HTA processes, reducing duplication for manufacturers and accelerating access.

Joint Clinical Assessment (JCA)

A comparative clinical assessment carried out by Member State assessors under a Coordination Group, producing a JCA report that national HTA bodies must 'duly consider'. Scope is defined by a PICO (Population, Intervention, Comparators, Outcomes) framework consolidated from all participating Member States.

Joint Scientific Consultation (JSC)

Pre-submission scientific advice on the evidence the developer plans to generate. Optional but strongly encouraged. JSC is non-binding and confidential, and runs in parallel with EMA scientific advice where appropriate.

JCA consolidates PICO questions across all interested Member States into a single assessment. In practice, early JCAs have produced wide PICO matrices with multiple comparators not all studied in the pivotal trial. Manufacturers must plan evidence-generation strategies early — typically starting in Phase II — to cover the likely PICO. JSC is the principal mechanism for getting visibility on the eventual PICO matrix.

• JCA is launched alongside the EMA marketing-authorisation procedure.
• The JCA report is finalised within 30 days of EMA CHMP opinion.
• National HTA bodies use the JCA as input; national pricing and reimbursement timelines run as before.
• Late JCA dossier submission delays the entire access pathway — sponsors who under-resource HTAR pay the price downstream.

1. Notify the Coordination Group of intent to submit an EMA application 9 months before submission.
2. Engage JSC for high-uncertainty technologies — early evidence-design alignment is the single biggest determinant of JCA outcome.
3. Prepare the JCA dossier in parallel with the EMA dossier; the JCA dossier reuses MAA data but is structured to the PICO matrix.
4. Respond to the Assessment Team's questions within tight statutory deadlines.
5. Plan post-launch evidence (RWE, registries) to address residual uncertainty flagged in the JCA report.

JCA for medical devices is selective: the Coordination Group identifies a small number of Class IIb implantables, Class III devices and Class D IVDs each year based on clinical impact, unmet need and EU-level added value. Selection is published in annual work programmes. For devices not selected, national HTA continues unchanged.

• Pivotal-trial comparator choice must anticipate the EU PICO matrix, not just the EMA primary endpoint requirements.
• Patient-relevant outcomes (HRQoL, functional status) carry more weight in JCA than in many national HTAs historically.
• Subgroup data and indirect treatment comparisons should be planned, not added late.
• RWE plans should be presented as part of the JSC, including registry strategy and post-launch data commitments.
• Health-economic modelling remains national, but the clinical inputs are now harmonised at EU level.